pharma · No medical condition. · Breast cancer
George Institute for
The George Institute
George Institute for clinical programs — 187 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Sydney, NSW 2042, AU
- Founded
- 1999
- Employees
- 841
- Programs
- 406
- Drugs
- 522
- Patents
- 0
George Institute for projects
187 ClinicalTrials.gov programs sponsored by George Institute for.
George Institute for has 187 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
-
The George Institute
Cytomegalovirus infection post allogeneic allogeneic HLA-identical familial PHT
1 trial -
2016/2369
The George Institute
pediatric cancer
1 trial -
2017/2558
The George Institute
Resectable mucosal melanomas
1 trial -
2020-004696-41
The George Institute
Newly diagnosed, non-metastatic early-stage triple-negative or HER2+ breast cancer
1 trial -
2020/3093 NIRADO
The George Institute
DNA repair-deficient or platinum-sensitive solid tumors
1 trial -
2021/3330 HOLMBRAVE
The George Institute
Non resectable Hepatocellular carcinoma (HCC)
1 trial -
2022/3418 INDIGO
The George Institute
Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.
1 trial -
2023/3610 NEOSARC
The George Institute
Undifferentiated pleomorphic sarcoma and Dedifferentiated liposarcoma
1 trial -
2023/3668
The George Institute
Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined as a score 1+ on immunohistochemistry [IHC] or as an IHC score 2+ and negative results on in situ hybridization (ISH) (cohort 2) ABC, and any hormone receptor (HR) status, who have progressed on trastuzumab deruxtecan (T-DXd). In addition to previous T-DXd, patients with HER2-pos tumors must have received prior treatment with trastuzumab (+/- pertuzumab) and taxanes and may have received T-DM1. Patients with HER2-low tumors must have received prior treatment with taxanes. Patients with HR-positive (HR+) and HER2-low tumor must have received prior treatment with endocrine therapy and CDK4/6 inhibitors.
1 trial -
2024/3967
The George Institute
Advanced non-small cell lung cancer
1 trial -
2025-521877-14-00
The George Institute
Traumatic spinal cord injury
1 trial -
2G-MSC-GVHD
The George Institute
Patients who have developed acute GVHD refractory to corticosteroids and ruxolitinib or that are not eligible to receive ruxolitinib
1 trial -
68Ga-FAPI-46
The George Institute
Triple-negative breast cancer (TNBC) patients at high risk of relapse
1 trial -
68Ga-FAPI-46
The George Institute
Non-metastatic Pancreatic ductal adenocarcinoma
1 trial -
ABP-2019
The George Institute
locally advanced (stage III) and not suitable for curative treatment, or metastatic (stage IV) ALK+ NSCLC, ALK+ NSCLC
1 trial -
ADJUBIL
The George Institute
Biliary tract cancer
1 trial -
ADMSC-fib safety and efficacy in patients with chronico wounds
The George Institute
chronic wounds
1 trial -
ALDESLEUKIN for Germ Cell Tumors refractory to salvage chemotherapy
The George Institute
Germ Cell Tumors refractory to salvage chemotherapy
1 trial -
ARI-HER2
The George Institute
Patients with HER2Positive Advanced Breast Cancer
1 trial -
ARICEPT 10mg comprimidos recubiertos con película
The George Institute
Parkinson's disease
1 trial -
ASP3082, DEXTROSE INJECTION / BRADEX 5%
The George Institute
Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma
1 trial -
ASPIRE
The George Institute
Patients with resectable hepatocellular carcinoma (amenable R0 resection) at high risk of recurrence.
1 trial -
ATEZOLIZUMAB
The George Institute
Patients with metastatic tumours (colorectal, non-small cell lung, renal and sarcoma)
1 trial -
AdaptNK –Cell Therapy for High-risk Myeloid Disease
The George Institute
Relapsed and/or refractory AML or MDS
1 trial -
AloCelyvir
The George Institute
mEtastatic Uveal Melanoma
1 trial -
Amimox filmdragerade tabletter for Need of Oral bone augmentation
The George Institute
Need of Oral bone augmentation
1 trial -
BAY 73-4506, AVELUMAB
The George Institute
Adult patients with advanced or metastatic solid tumors
1 trial -
BCN04-DASA
The George Institute
Human immunodeficiency virus
1 trial -
BDTX-4933-101
The George Institute
Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations
1 trial -
BOOST cells
The George Institute
Osteogenesis Imperfecta (OI) type III and severe type IV. Severe type of congenital Brittle bone disease.
1 trial -
BOTULINUM TOXIN , -
The George Institute
Myogenous temporomandibular disorders (TMDM)
1 trial -
Bleomycin medac, 15 000 RÜ süstelahuse pulber
The George Institute
VASCULAR MALFORMATION
1 trial -
Busulfan /ml concentrate for High-risk myeloïd malignancies
The George Institute
High-risk myeloïd malignancies
1 trial -
Byetta 10 micrograms solution for injection in pre-filled pen
The George Institute
Hypopituarism
1 trial -
C12-48
The George Institute
Recessive dystrophic epidermolysis bullosa (RDEB)
1 trial -
CART19-BE-02
The George Institute
Acute lymphoid leukemia
1 trial -
CARTBCMA-HCB-01
The George Institute
Multiple Myeloma
1 trial -
CAT-01
The George Institute
Cervical carcinoma
1 trial -
CBD-ESPRIT
The George Institute
Remitted early phase schizophrenia
1 trial -
CIALIS 5 mg film-coated tablets
The George Institute
sexual/ erectile function in women and men after treatment for rectal cancer
1 trial -
CIRCULATE-SPAIN-01
The George Institute
Localised Colon Cancer (stage II-III)
1 trial -
CL1-65487-003
The George Institute
Acute Myeloid Leukemia (AML)
1 trial -
CL1-95012-001
The George Institute
Soild Tumors
1 trial -
CL1-95029-002
The George Institute
MSI-H/dMMR Gastric cancer, MSI-H/dMMR Gastroesophageal-junction Cancer
1 trial -
CL1-95035-001
The George Institute
MTAP-deleted advanced or metastatic solid tumors
1 trial -
CLEAN-DUCT
The George Institute
Extrahepatic cholangiocarcinoma (eCCA)
1 trial -
CSET 2020/3187
The George Institute
Adult patients with metastatic and/or unresectable Non-Small Cell Lung Cancer (NSCLC) who progressed on at least one line and not more than three lines of prior therapy for metastatic/unresectable NSCLC
1 trial -
CSET 2022-3571
The George Institute
Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.
1 trial
Frequently asked questions
How many clinical projects does George Institute for have?
187 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.